Coral Genomics develops new clinical tests to help providers streamline prior authorization and select the most effective medication for a particular patient focusing on autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. It has also identified a unique population of non-responder patients and is working with drug developers to address this unmet medical need.